APA (7th ed.) Citation

CB, B., JB, E., JE, R., J, O., RM, L., JA, B., . . . H, G. (2012). Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: A structured literature review. The oncologist, 17(1), 135. https://doi.org/10.1634/theoncologist.2011-0111

Chicago Style (17th ed.) Citation

CB, Boers-Doets, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, and Gelderblom H. "Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review." The Oncologist 17, no. 1 (2012): 135. https://doi.org/10.1634/theoncologist.2011-0111.

MLA (9th ed.) Citation

CB, Boers-Doets, et al. "Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review." The Oncologist, vol. 17, no. 1, 2012, p. 135, https://doi.org/10.1634/theoncologist.2011-0111.